A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Janssen Research & Development LLC
The purpose of this study is to compare the effects of amivantamab in combination with standard of care chemotherapy (FOLFIRI) against cetuximab or bevacizumab in combination with FOLFIRI in participants with metastatic Colorectal Cancer (CRC) that lack mutations in genes called KRAS/NRAS and BRAF. Cetuximab, bevacizumab and FOLFIRI therapy is already used to treat participants with your type of cancer.
Enrollment Form
This study is currently enrolling.